is retatrutide a glp-1 drug Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, CBS News investigation Retatrutide Research: Triple Agonist Mechanism

Additional treatments such as muscle preserving agents or intermittent dosing strategies may need to be investigated

Subsequently, oral formulations and once weekly injections were developed in the 2010s and liraglutide was the first GLP-1 receptor agonist approved for the treatment of obesity in 2014

[97] observed a potential association between semaglutide and NAION, with incidence rates of 4.28 and 7.64 per 1,000 person-years in patients with T2DM and those who were overweight or obese, respectively, over 36 months

The BBPS score is obtained by adding a score over 3 for each of the 3 colonic segments, with a total score of 9, signifying excellent preparation, and a minimum score of 0, signifying very poor preparation [27]

Repeated cycles of initiation, interruption and re-initiation of these drugs might induce body weight and HbA 1c fluctuations two risk factors for cardiovascular and microvascular events

mean follow-up: 5.09 years) and as-treated (HR 1.07, 95% CI 0.851.36